Stockscreener 앱 받기
6.19
1.90%
-0.12
전일 마감가:
$6.31
열려 있는:
$6.31
하루 거래량:
721.05K
Relative Volume:
0.82
시가총액:
$494.00M
수익:
$116.30M
순이익/손실:
$17.73M
주가수익비율:
29.48
EPS:
0.21
순현금흐름:
$20.88M
1주 성능:
-5.06%
1개월 성능:
-2.37%
6개월 성능:
-46.17%
1년 성능:
+0.00%
1일 변동 폭
$6.165
$6.335
1주일 범위
$6.12
$6.61
52주 변동 폭
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
명칭
Niagen Bioscience Inc
전화
310-388-6706
주소
10900 WILSHIRE BLVD, LOS ANGELES
NAGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
6.19 | 503.58M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 개시 | Canaccord Genuity | Buy |
| 2022-08-16 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-08-11 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | 개시 | ROTH Capital | Buy |
| 2019-10-16 | 개시 | Oppenheimer | Outperform |
| 2019-02-14 | 개시 | B. Riley FBR | Buy |
| 2017-11-27 | 재개 | H.C. Wainwright | Buy |
| 2017-09-25 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-03 | 개시 | Rodman & Renshaw | Buy |
모두보기
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Will Niagen Bioscience Inc outperform its industry peers2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Exit Recap: What is the Moat Score of Niagen Bioscience IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn
Can Niagen Bioscience’s (NAGE) HSA Access Shift Redefine Its Direct-to-Consumer Growth Strategy? - Yahoo Finance
Revenue Check: Is now the right time to enter Niagen Bioscience IncTrade Exit Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen By Investing.com - Investing.com Nigeria
NAGE: Niagen Bioscience advances NAD health solutions, expanding into IV, telehealth, and skincare - TradingView — Track All Markets
Niagen Bioscience (NAGE) Valuation In Focus As Investor Summit Appearance Nears - Yahoo Finance
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S. - morningsun.net
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen - Investing.com
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.* - New Castle News
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative? - simplywall.st
Insider Buy: Whats the beta of Niagen Bioscience Inc stockEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Is Niagen Bioscience Inc. stock resilient to inflationMarket Growth Report & Entry and Exit Point Strategies - Улправда
Niagen Bioscience, Inc. (NAGE) Stock Analysis: 140.85% Upside Potential Captures Investor Attention - DirectorsTalk Interviews
Published on: 2026-01-08 21:02:30 - Улправда
Will Niagen Bioscience Inc. stock benefit from sector rotationWeekly Profit Report & Fast Momentum Stock Entry Tips - ulpravda.ru
Will Niagen Bioscience Inc. stock deliver shareholder valueJuly 2025 Momentum & Consistent Return Strategy Ideas - Улправда
Why Niagen Bioscience Inc. stock attracts global investorsJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
Published on: 2026-01-09 00:19:58 - Улправда
Should I hold or sell Niagen Bioscience Inc. stock in 20252025 Bull vs Bear & Weekly High Potential Alerts - ulpravda.ru
Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market (NASDAQ:NAGE) - Seeking Alpha
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
What date does Niagen Bioscience, Inc.'s (NAGE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE - MarketBeat
BSW Wealth Partners Takes Position in Niagen Bioscience, Inc. $NAGE - Defense World
Niagen Bioscience acquires existing nicotinamide riboside patent portfolio - MSN
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast By Investing.com - Investing.com Nigeria
Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast - marketscreener.com
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast - PharmiWeb.com
Niagen Bioscience (NAGE) Secures Key Patents, Boosts Revenue For - GuruFocus
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast - Investing.com
Niagen Bioscience (NAGE) Secures Exclusive Ownership of Key Pate - GuruFocus
Niagen Bioscience Secures Full Ownership of Key NR Patents - TipRanks
Niagen Bioscience secures full ownership of key NR patents - MSN
Niagen Bioscience acquires existing core nicotinamide riboside patent portfolio from Queen's University Belfast - marketscreener.com
Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast - TradingView — Track All Markets
Niagen Bioscience (NAGE) secures full patent rights via new QUB deal - Stock Titan
Niagen Bioscience (STU:OCD1) EV-to-OCF : 19.90 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (STU:OCD1) EV-to-FCF : 20.14 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (FRA:OCD1) EV-to-OCF : 19.90 (As of Dec. 21, 2025) - GuruFocus
Market Outlook: Should I hold or sell Niagen Bioscience Inc. stock in 20252025 EndofYear Setup & Daily Profit Focused Screening - ulpravda.ru
Is Niagen Bioscience Inc. stock a safe buy before earningsWatch List & High Accuracy Buy Signal Tips - Улправда
Why Niagen Bioscience Inc. (OCD1) stock stays undervaluedPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Why Niagen Bioscience Inc. stock could see breakout soonStop Loss & AI Based Trade Execution Alerts - Улправда
Volume Recap: Why Niagen Bioscience Inc. (OCD1) stock stays undervalued2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Улправда
Can Niagen Bioscience Inc. stock outperform in 2025 bull market2025 Stock Rankings & Smart Allocation Stock Tips - DonanımHaber
Published on: 2025-12-19 14:46:11 - DonanımHaber
Will Niagen Bioscience Inc. stock deliver better than expected guidanceJuly 2025 Short Interest & Expert Curated Trade Setups - Улправда
Is Niagen Bioscience Inc. stock vulnerable to regulatory risksQuarterly Investment Review & Free High Return Stock Watch Alerts - Улправда
Niagen Bioscience Inc (NAGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Niagen Bioscience Inc 주식 (NAGE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
| Fried Robert N | Chief Executive Officer |
Apr 09 '25 |
Option Exercise |
3.30 |
66,667 |
220,001 |
1,038,981 |
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
4.73%
0.92%
자본화:
|
볼륨(24시간):